New drug combo aims to shrink head and neck tumors
Disease control
Not yet recruiting
This study tests whether adding cetuximab (a targeted therapy) to standard immunotherapy (pembrolizumab or finotonlimab) plus chemotherapy helps control advanced head and neck cancer better than immunotherapy plus chemo alone. About 316 adults aged 18-70 with recurrent or metasta…
Phase: PHASE3 • Sponsor: Ji Dongmei • Aim: Disease control
Last updated May 01, 2026 15:58 UTC